In which pharmacies or platforms can Mirdametinib be purchased?

Up to now, Mirdametinib (Mildametinib, trade name Gomekli) has been approved by the United StatesFDA for treatment on 20252month11 2 Patients aged 2 years and older with neurofibromatosis type 1 (NF1) combined with unresectable plexiform neurofibromas, including both adults and children. The drug is not yet widely available in China or globally, and there are no regulatory approved generic versions. Currently, only SpringWorks Therapeutics serves as the original manufacturer to provide approved regular products.

Due to the lack of widespread marketing channels, midametinib is currently not available in regular pharmacies or medical insurance hospitals in China. For research and experimental research purposes, there are a few overseas scientific research chemical suppliers (such as Adooq, Selleck, MedKoo etc.) provide research compounds of midametinib (PD‑0325901), but these are only used for scientific research experiments and are clearly marked "not for sale to patients." Therefore, these platforms are not qualified to provide patients with therapeutic dosage forms or regular drugs and cannot be used for clinical treatment.

If patients or families want to obtain midametinib, a more compliant way is to participate in international clinical trial projects, such as the ReNeu IIb phase study or the compassionate use channel provided by SpringWorks ; or wait. After formal approval in European and American countries, original drugs can be obtained through formal purchasing and medical channels. Currently, there are no reliable retail pharmacies, cross-border e-commerce or domestic treatment platforms that can legally supply Gomekli.

Generally speaking, midametinib has not yet entered retail or medical insurance channels, and is limited to research or pending approval status in domestic and foreign markets. Any midametinib that claims to be available for purchase in public pharmacies, online platforms or private purchasing agencies should carefully verify the legality of its source and consult professional blood neurologists and formal regulatory authorities to ensure drug safety and treatment compliance.

Reference materials:https://www.drugs.com/